Patents by Inventor David M. Rothstein

David M. Rothstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING ORAL MUCOSITIS
    Publication number: 20230218633
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 13, 2023
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Methods of treating oral mucositis
    Patent number: 11612608
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 28, 2023
    Assignee: galera labs, llc
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • METHODS OF TREATING ORAL MUCOSITIS
    Publication number: 20200215077
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Application
    Filed: February 27, 2020
    Publication date: July 9, 2020
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Methods of treating oral mucositis
    Patent number: 10610533
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: April 7, 2020
    Assignee: Galera Labs, LLC
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • METHODS OF TREATING ORAL MUCOSITIS
    Publication number: 20180333421
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Application
    Filed: December 14, 2017
    Publication date: November 22, 2018
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Methods of treating oral mucositis
    Patent number: 9855279
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: January 2, 2018
    Assignee: GALERA LABS, LLC
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Methods of treating oral mucositis
    Patent number: 9642861
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: May 9, 2017
    Assignee: GALERA LABS, LLC
    Inventors: David M. Rothstein, Chris Murphy, Vivian Wong, Glenn Kazo
  • METHODS OF TREATING ORAL MUCOSITIS
    Publication number: 20140343028
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Application
    Filed: June 11, 2014
    Publication date: November 20, 2014
    Inventors: David M. ROTHSTEIN, Chris MURPHY, Vivian WONG, Glenn KAZO
  • Methods Of Treating Oral Mucositis
    Publication number: 20080269185
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Application
    Filed: October 12, 2007
    Publication date: October 30, 2008
    Applicant: ActivBiotics
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Screening immunomodulatory agents by CTLA-4 upregulation
    Patent number: 7014998
    Abstract: Screens that directly or indirectly measure or qualitatively observe CTLA-4 expression or function by animals or cell cultures, or that indirectly measure dependence of an agent on CTLA-4 by comparison to animals or cell cultures that lack CTLA-4, identify agents that are useful in immunosuppression and the generation of immunologic tolerance for the prevention and treatment of transplant rejection, autoimmune and inflammatory diseases.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: March 21, 2006
    Assignee: Yale University
    Inventors: David M. Rothstein, Giacomo P. Basadonna
  • Screening for antibiotics
    Patent number: 6534278
    Abstract: Assays for the detection of &bgr;-lactamase induction can be used to identify compounds that kill bacteria (i.e., bacteriocidal activity) or inhibit bacterial growth (i.e., bacteriostatic activity). The &bgr;-lactamase can be encoded, for example, by a &bgr;-lactamase gene carried by a bacterial host. The identified compounds can be use to treat bacterial infections in organisms such as mammals. The new methods can be used, for example, for high throughput screening of libraries of potential inhibitors.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: March 18, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: David M. Rothstein
  • Method for treating cystic fibrosis
    Patent number: 6528488
    Abstract: Methods for treating cystic fibrosis in a mammal that include administering to the mammal an effective amount of a histatin, a histatin fragment, or a histatin-related peptide are disclosed.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: March 4, 2003
    Assignee: Demegen, Inc.
    Inventors: Peter Spacciapoli, David M. Rothstein, Phillip M. Friden
  • METHOD FOR TREATING CYSTIC FIBROSIS
    Publication number: 20020077282
    Abstract: Methods for treating cystic fibrosis in a mammal that include administering to the mammal an effective amount of a histatin, a histatin fragment, or a histatin-related peptide are disclosed.
    Type: Application
    Filed: January 8, 1999
    Publication date: June 20, 2002
    Inventors: PETER SPACCIAPOLI, DAVID M. ROTHSTEIN, PHILLIP M. FRIDEN
  • Screening immunomodulatory agents by CTLA-4 upregulation
    Publication number: 20020041849
    Abstract: Screens that directly or indirectly measure or qualitatively observe CTLA-4 expression or function by animals or cell cultures, or that indirectly measure dependence of an agent on CTLA-4 by comparison to animals or cell cultures that lack CTLA-4, identify agents that are useful in immunosuppression and the generation of immunologic tolerance for the prevention and treatment of transplant rejection, autoimmune and inflammatory diseases.
    Type: Application
    Filed: September 24, 2001
    Publication date: April 11, 2002
    Inventors: David M. Rothstein, Giacomo P. Basadonna
  • Screening for antibiotics
    Patent number: 6153381
    Abstract: Assays for the detection of .beta.-lactamase induction can be used to identify compounds that kill bacteria (i.e., bacteriocidal activity) or inhibit bacterial growth (i.e., bacteriostatic activity). The .beta.-lactamase can be encoded, for example, by a .beta.-lactamase gene carried by a bacterial host. The identified compounds can be use to treat bacterial infections in organisms such as mammals. The new methods can be used, for example, for high throughput screening of libraries of potential inhibitors.
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: November 28, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: David M. Rothstein
  • Construct and method for expression of tetracycline resistance genes in E. Coli
    Patent number: 5384259
    Abstract: The present invention relates to DNA sequences useful in directing low to moderate expression of proteins in E. coli. The sequences are on based on modification of the repressor binding site of the tetA gene of transposon Tn10.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: January 24, 1995
    Assignee: American Cyanamid Company
    Inventors: David M. Rothstein, Gordon G. Guay
  • Genetic system for micromonospora
    Patent number: 5024948
    Abstract: A culture comprising the microorganism Micromonospora echinospora ssp. calichensis DR46 (ATCC-53591), which produces complementing factor, is described and disclosed.
    Type: Grant
    Filed: March 6, 1987
    Date of Patent: June 18, 1991
    Assignee: American Cyanamid Company
    Inventors: David M. Rothstein, Susan F. Love, Ellen Z. Baum